2026 Global: Hospital Acquired Disease Testing Market-Competitive Review (2032) report
Description
The 2026 Global: Hospital Acquired Disease Testing Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Leading players in the hospital acquired infection (HAI) testing market provide molecular and immunodiagnostic capabilities designed to rapidly identify pathogens implicated in nosocomial outbreaks. Roche Diagnostics, based in Basel, Switzerland, offers high throughput platforms and multiplex panels that support screening for MRSA, C difficile, and other HAIs. Abbott, headquartered in Abbott Park, United States, emphasizes integrated assays and point of care options that enable timely clinical decisions in acute care. Thermo Fisher Scientific, headquartered in Waltham, United States, provides a broad portfolio of nucleic acid amplification tests, automation, and reagents for scalable hospital laboratory workflows. Danaher, with its Cepheid division, anchored in Washington DC, United States, dominates rapid PCR testing through the Xpert family and related panels used for infection control and outbreak management. BioMérieux, based in Marcy Etoile, France, anchors syndromic multiplex PCR with FilmArray and related platforms, widely deployed for HAI surveillance and triage. These capabilities shape practice.
Beyond the core molecular platforms, the hospital acquired infection testing market includes instrument makers and assay developers that enhance infection control programs across care environments. BD, headquartered in Franklin Lakes, United States, markets automated, high throughput solutions such as BD MAX for nucleic acid amplification tests that support MRSA, C difficile, and related panels. DiaSorin, headquartered in Saluggia, Italy, complements serology and targeted immunoassays with LIAISON and other platforms used for pathogen surveillance. Qiagen, based in Hilden, Germany, offers QIAstat Dx and associated testing panels that deliver rapid multiplex results for respiratory and bloodstream infections in hospital laboratories. Grifols, headquartered in Barcelona, Spain, provides the Procleix NAT testing platform and related diagnostic assays that support blood bank safety and infection screening in clinical settings. Siemens Healthineers, headquartered in Erlangen, Germany, contributes multiplex imaging and molecular testing solutions that integrate with hospital information systems to streamline workflow and infection control audits.
Collectively, the ten companies described here illustrate a market characterized by rapid innovation, broad geographic distribution, and increasing integration with hospital information systems. Roche Diagnostics and Abbott lead volume through global reach and diverse product portfolios that span automated platforms, point of care testing, and companion assays. Thermo Fisher Scientific and Danaher emphasize scalable nucleic acid amplification test workflows for high throughput laboratories, with rapid platforms provided by Danaher's divisions. BioMérieux, BD, and DiaSorin complement immunoassay and molecular capabilities with targeted panels and serology. Qiagen, Grifols, and Siemens Healthineers add breadth through multiplex assays, specialized nucleic acid tests, and imaging and analytics that support infection control and surveillance. As hospitals seek faster turnaround, stronger assay panels, and safer screening, competition among these players is likely to intensify, driving cost efficiency, cross platform interoperability, and improved clinical outcomes in hospital acquired infections. Continued collaboration and standardization will support evidence based practice.
Leading players in the hospital acquired infection (HAI) testing market provide molecular and immunodiagnostic capabilities designed to rapidly identify pathogens implicated in nosocomial outbreaks. Roche Diagnostics, based in Basel, Switzerland, offers high throughput platforms and multiplex panels that support screening for MRSA, C difficile, and other HAIs. Abbott, headquartered in Abbott Park, United States, emphasizes integrated assays and point of care options that enable timely clinical decisions in acute care. Thermo Fisher Scientific, headquartered in Waltham, United States, provides a broad portfolio of nucleic acid amplification tests, automation, and reagents for scalable hospital laboratory workflows. Danaher, with its Cepheid division, anchored in Washington DC, United States, dominates rapid PCR testing through the Xpert family and related panels used for infection control and outbreak management. BioMérieux, based in Marcy Etoile, France, anchors syndromic multiplex PCR with FilmArray and related platforms, widely deployed for HAI surveillance and triage. These capabilities shape practice.
Beyond the core molecular platforms, the hospital acquired infection testing market includes instrument makers and assay developers that enhance infection control programs across care environments. BD, headquartered in Franklin Lakes, United States, markets automated, high throughput solutions such as BD MAX for nucleic acid amplification tests that support MRSA, C difficile, and related panels. DiaSorin, headquartered in Saluggia, Italy, complements serology and targeted immunoassays with LIAISON and other platforms used for pathogen surveillance. Qiagen, based in Hilden, Germany, offers QIAstat Dx and associated testing panels that deliver rapid multiplex results for respiratory and bloodstream infections in hospital laboratories. Grifols, headquartered in Barcelona, Spain, provides the Procleix NAT testing platform and related diagnostic assays that support blood bank safety and infection screening in clinical settings. Siemens Healthineers, headquartered in Erlangen, Germany, contributes multiplex imaging and molecular testing solutions that integrate with hospital information systems to streamline workflow and infection control audits.
Collectively, the ten companies described here illustrate a market characterized by rapid innovation, broad geographic distribution, and increasing integration with hospital information systems. Roche Diagnostics and Abbott lead volume through global reach and diverse product portfolios that span automated platforms, point of care testing, and companion assays. Thermo Fisher Scientific and Danaher emphasize scalable nucleic acid amplification test workflows for high throughput laboratories, with rapid platforms provided by Danaher's divisions. BioMérieux, BD, and DiaSorin complement immunoassay and molecular capabilities with targeted panels and serology. Qiagen, Grifols, and Siemens Healthineers add breadth through multiplex assays, specialized nucleic acid tests, and imaging and analytics that support infection control and surveillance. As hospitals seek faster turnaround, stronger assay panels, and safer screening, competition among these players is likely to intensify, driving cost efficiency, cross platform interoperability, and improved clinical outcomes in hospital acquired infections. Continued collaboration and standardization will support evidence based practice.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
